Hologic announced an agreement with the Centers for Disease Control and Prevention (CDC) to contribute to the development of H5N1 bird flu tests. This initiative involves developing probes and primers that can be integrated into Lab-Developed Tests (LDTs) for H5N1 identification.
This partnership leverages Hologic's expertise in molecular diagnostics and its Panther system, which is capable of high-throughput testing. Contributing to public health initiatives like H5N1 test development can open new avenues for the company's diagnostic solutions.
The collaboration underscores Hologic's role in addressing emerging infectious disease threats and could position the company for future opportunities in pandemic preparedness and response.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.